O-1A Guide
O-1A for Health Economics Researchers: ISPOR Award Records, NIH R01 Grant Evidence, and Research Publication Framework in 2026
Health economists work across academic departments, pharmaceutical companies, and government agencies, generating evidence in multiple professional communities simultaneously. This article maps ISPOR awards, NIH R01 grant records, NBER affiliations, and health technology assessment citations against the O-1A criteria for a field that straddles economics and clinical research.
Why health economics evidence requires careful organization
Health economics occupies a position between academic economics, public health, and pharmaceutical outcomes research that creates a distinctive evidence challenge for O-1A petitions. A health economist working on pharmaceutical pricing may publish in Value in Health, collaborate with a clinical trial team, present at ISPOR meetings, and consult for a government health agency — all in the same year. This cross-disciplinary activity generates evidence in multiple domains that can appear scattered if the petition does not impose a clear organizational framework. The petitioner's immigration attorney should identify the primary disciplinary home — academic economics, health policy, or industry outcomes research — and organize the evidence around that framing before addressing secondary contributions from the other domains.
The field has two major professional societies relevant to O-1A petitions: the American Society of Health Economists (ASHEcon), which connects to the academic economics discipline, and the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), which connects to the pharmaceutical industry and health technology assessment community. A health economist with recognition from both societies has a broader evidence base than one recognized by only one. ISPOR in particular has a formal awards program, section leadership structure, and a fellowship designation that can be used for the membership criterion, making it a useful organizational home for industry-based or consulting health economists who may not hold traditional faculty appointments.
NIH grant funding is the most powerful single credential in academic health economics and is frequently decisive for USCIS when documented correctly. NIH R01 awards in health economics most often come through the National Cancer Institute's Health Economics and Health Outcomes Research Branch, the National Institute on Aging's Division of Social Science Research, or through the Patient-Centered Outcomes Research Institute (PCORI) for comparative effectiveness work. Each funding source has its own competitive process and external peer review structure, and the petition should explain the funding agency, the typical funding rate for the relevant study section, and why the specific scientific merit of the petitioner's proposed work distinguished it from unfunded applications.
ISPOR awards and formal professional recognition
ISPOR's formal recognition program includes the Value in Health Best Paper Award, the ISPOR Excellence in Research Award, the Zitter Young Investigator Award for researchers within five years of their terminal degree, and section-specific recognitions within its Special Interest Groups, which cover areas ranging from health economics modeling to real-world evidence and HTA methodology. The Best Paper Award in particular is granted based on peer selection from among all papers published in Value in Health, ISPOR's flagship journal, during the prior year. Being identified by peer review as among the best contributions to that journal in a given year is a recognizable marker of field-level recognition that USCIS adjudicators can evaluate without specialist knowledge.
ASHEcon, the academic economics society most focused on health economics, holds a biannual conference and awards the Arrow Award, given to the best paper in health economics as judged by a panel of senior economists. The Arrow Award's selection process — named after the Nobel laureate whose 1963 paper on uncertainty and the welfare economics of medical care is considered foundational to the field — is rigorous and competitive. A health economist who has received the Arrow Award or who has been recognized at ASHEcon through paper awards or invited keynote status has evidence of recognition from peers who are themselves at the top of the academic discipline. This distinction matters when differentiating genuine peer recognition from ordinary conference acceptance.
Recognition from the International Health Economics Association (IHEA), which holds its World Congress every two years, and from regional affiliates in Europe, Asia, and Latin America, can support a national or international recognition argument for health economists whose work spans multiple country settings or who have been funded by multinational health agencies. IHEA's biennial awards are internationally peer-selected. For health economists who work in global health settings — examining healthcare markets in lower-income countries, or advising the WHO or World Bank on health financing — the IHEA and related international recognition framework may be the appropriate primary evidentiary track rather than the domestic ASHEcon track.
NIH R01 grants as original contribution evidence
A funded NIH R01 award in health economics functions simultaneously as evidence of original contributions and as evidence of recognition from experts in the field — the study section peer reviewers who scored the application are themselves accomplished researchers who determined that this project merited funding over the majority of applications received. The petition should include the public grant abstract from NIH RePORTER, the total award amount, the funding period, and the name of the study section or review group that evaluated the application. Peer review scores in percentile form are sometimes available through the funding agency and can be disclosed to show competitive standing, though they are not required.
PCORI and AHRQ also fund health economics research through competitive grant mechanisms. PCORI awards in particular are often large, multi-year, multi-site comparative effectiveness research projects. If the petitioner is a principal investigator on a PCORI award, the evidence framework is the same as for NIH: document the competitive award process, the independent review panel's role, the award amount, and the petitioner's specific research leadership within the project. AHRQ-funded health services research that includes health economics components can be documented similarly, though AHRQ's peer review process is somewhat less transparent than NIH's and may require a declaration from a study section participant to explain the competitive standards.
Publishing health economic models — decision-analytic models, cost-effectiveness analyses used by HTA bodies to make drug coverage decisions — in peer-reviewed journals or submitting them to regulatory authorities creates a distinctive original contribution argument. If a petitioner's cost-effectiveness framework has been cited in a NICE technology appraisal, an ICER assessment, or a formulary decision by a major payer, that adoption demonstrates major significance in a concrete and verifiable way. These citations may not appear in Google Scholar, but they appear in publicly available HTA reports from NICE, the Canadian Drug Agency, the Australian PBAC, and ICER that can be retrieved and submitted as exhibits.
Critical role in research centers and policy organizations
Health economists occupying critical roles include principal investigators leading NIH-funded research centers, faculty members directing health policy research institutes, and senior economists embedded in government agencies or consulting firms whose analytical work directly shapes coverage, reimbursement, or policy decisions. The critical role criterion requires showing that the petitioner's particular expertise was essential to the organization's mission, not just that they worked there. For academic health economists, this often means documenting their role as PI or co-PI on the center's main grants, their mentorship of doctoral students and postdoctoral researchers, and the unique methodological contributions that distinguished the center's research approach from other groups working on similar topics.
Health economists at NBER (the National Bureau of Economic Research) hold a particularly strong critical role argument, because NBER affiliates are selected through a formal vetting process by existing members and cannot self-nominate. NBER affiliation requires demonstrated research excellence and is limited to economists whose work is recognized by the existing research community. An NBER Research Associate or Faculty Research Fellow appointment is not merely an honorary membership — it comes with access to the NBER working paper series, data resources, and conference invitations, all of which require documented research standing. A petition that documents the petitioner's NBER affiliation, with a letter from a program director explaining the selection criteria, has strong evidence for both the critical role and membership criteria.
For health economists at government agencies — CMS, FDA's Center for Drug Evaluation and Research, or HHS's Office of the Assistant Secretary for Planning and Evaluation — the critical role argument centers on the connection between the petitioner's analytical work and specific regulatory or policy outputs. A health economist who designed the analytical framework used in a major Medicare final rule, or who developed the cost-effectiveness methodology that informed an FDA label change, has made a contribution categorically different from providing general policy analysis. These connections can be documented through the Federal Register, which publishes proposed and final rules with detailed analytical methods sections, and through agency declarations describing the petitioner's specific technical contributions.
High salary benchmarks and evidence thresholds
The BLS OEWS data for economists (SOC 19-3011) provides the primary salary benchmark for health economists in academic and research positions. The 90th percentile for economists nationally as of 2025 OEWS data is approximately $195,000 in annual wages, though the metropolitan area adjustment is important: health economists in Boston, New York, and San Francisco markets will find that the local 90th percentile is substantially higher than the national figure, and the petition should use the metropolitan-area-specific data when the petitioner is employed in a high-cost labor market. The OEWS tables by metropolitan statistical area are publicly available on the BLS website and can be submitted as exhibits without further authentication.
For health economists at consulting firms or pharmaceutical companies, the relevant benchmark may be the health specialties SOC category or a pharmaceutical industry-specific survey rather than the general economist category, depending on how the employer classifies the position. The petition should use the most precisely applicable SOC code and provide documentation explaining why that code applies. A health economist classified as a medical and health services manager rather than as an economist will face a different benchmark comparison, so it is worth confirming with the employer what category the position is reported under before selecting the comparison dataset.
For academic health economists, total compensation often includes base salary, summer salary from research grants, and consulting income from pharmaceutical companies or government agencies. The high salary criterion allows the petition to aggregate these sources if they are compensation for health economics services. A faculty member whose base salary falls below the 90th percentile but whose total annualized compensation — base plus grant-funded summer salary plus independent consulting fees — exceeds the threshold has a legitimate high salary argument, provided all components are documented with W-2s, 1099s, or consulting agreement terms. The petition should be transparent about the composition of total compensation and explain why aggregating these components is appropriate under the applicable regulatory standard.
Building a complete health economics evidence strategy
A complete evidence file for a health economics petition typically requires at least three or four distinct criteria with primary evidence, plus a narrative that explains why the research is significant enough to place the petitioner among the small percentage of health economists who have risen to the top of the field. The narrative structure matters as much as the raw evidence: a USCIS adjudicator who does not know what ISPOR is, or what a study section score means, cannot draw appropriate conclusions from the evidence without explanation. The petition brief should assume a reader who is intelligent but has no subject-matter expertise in health economics and supply every contextual detail needed to evaluate the evidence correctly.
Timing considerations for health economics petitions are often driven by academic appointment cycles, grant timelines, or consulting contract structures. A health economist in the middle of a major NIH R01 award who petitions during the active grant period has stronger critical role evidence than one who petitions after the grant period ends. If the petitioner is transitioning from a postdoctoral fellowship to a faculty position — a common career stage for O-1A consideration — the petition should be timed to the faculty appointment start date, with the employer on record as the I-129 petitioner. The H-1B cap and lottery system is the primary alternative for many health economists, and the O-1A's cap-exempt status makes it a preferable path for those who can meet the extraordinary ability standard.
Expert letters for health economics petitions should come from economists who can evaluate the petitioner's work against the full population of health economics researchers, not just those working in the petitioner's specific subspecialty. A reviewer from a complementary subfield — comparative effectiveness research evaluating a cost-effectiveness modeler, or a health finance economist evaluating a market competition researcher — brings an external perspective that is more credible to USCIS than a letter from a direct collaborator whose objectivity may be questioned. Ideally, the pool of letter writers includes at least one non-U.S. expert from a major international health economics group, which reinforces the national or international acclaim standard that underpins all O-1A extraordinary ability claims.
What we typically gather for this kind of case
| Document | Where to source | Why it matters |
|---|---|---|
| Peer-reviewed publications | Web of Science / Scopus exports | Anchors original-contributions and authorship criteria |
| Citation analysis | Google Scholar profile + ESI top-1% data | Quantifies major significance in the field |
| Salary benchmark | BLS OEWS for SOC code + locality | Documents high-salary criterion at 90th-percentile or above |
| Critical-role letters | Direct supervisor + program director | Establishes role's importance, not just title |
What we see go wrong, again and again
- 01Treating extraordinary ability as a credentials checklist rather than a story of field-wide impact.
- 02Submitting bibliometric data (h-index, citation counts) without explaining what makes those numbers high relative to peers in the same sub-field.
- 03Relying on letters from collaborators or co-authors rather than independent experts who can speak to influence.
See if you qualify
Lando reviews your background against the O-1A visa criteria and tells you honestly where you stand. Free, no commitment.